USFDA Turns to Indian Drugmakers Amid Critical Cancer Medicine Shortage; Pharma Stocks Draw Attention

Summary:
The USFDA has approached Indian pharmaceutical manufacturers through the IDMA to help address a shortage of ifosfamide, a chemotherapy drug used in the treatment of several cancers. The regulator is seeking companies capable of supplying 1 g and 3 g injections, including firms that are not USFDA-registered but have strong compliance records. The shortage has been linked to manufacturing disruptions and supply chain challenges, with constraints expected to continue through 2026. The development has put Indian drugmakers such as Cipla, Zydus Life, Alkem Labs, Aurobindo Pharma, and Dr. Reddy’s Laboratories in focus. India, which supplies around 20% of the world’s generic medicines, exported pharmaceuticals worth ₹75,803.50 crore to the US in FY26, accounting for nearly 35% of its total drug exports. 

The United States Food and Drug Administration (USFDA) has reached out to Indian pharmaceutical companies through the Indian Drug Manufacturers’ Association (IDMA) to help ease a shortage of ifosfamide, a widely used generic chemotherapy medicine prescribed for cancers such as testicular, bladder, and lung cancer, according to a Mint report.

The US regulator has requested assistance in identifying Indian manufacturers that can promptly supply ifosfamide injections in 1 g and 3 g strengths to support the US market, where availability of the drug remains constrained.

In a communication sent to its members on June 19, 2026, IDMA stated that the USFDA’s India Office is seeking details of companies that either currently manufacture the product or possess the capability to produce it for domestic or international markets.

The association further noted that the USFDA is open to sourcing the medicine from facilities that are not registered with the US regulator, provided they have a proven record of regulatory compliance. The agency is also willing to consider products already approved and sold in markets outside the United States.

The shortage has reportedly been caused by technical issues at a contract manufacturing facility operated for Baxter International, along with supply chain disruptions stemming from geopolitical tensions in West Asia. The report indicated that supply constraints are expected to continue throughout 2026.

While no individual companies were named, pharmaceutical stocks such as Cipla, Zydus Life, and Alkem Laboratories are likely to remain under investor scrutiny. Other firms that may attract attention include Aurobindo Pharma, known for its injectable drug capabilities, Dr. Reddy’s Laboratories with its oncology-focused API and formulation portfolio, and Cipla, which maintains a strong presence in oncology injectables.

India is home to around 10,500 pharmaceutical manufacturing units, including more than 350 facilities approved by the USFDA. The country supplies roughly 20% of the world’s generic medicines and ranks third globally in pharmaceutical production by volume.

According to Commerce Ministry data, India exported medicines worth ₹75,803.50 crore to the United States during FY26, representing nearly 35% of the country’s total pharmaceutical exports of ₹2.18 trillion.